$RGBP Currently CheckPoint Immunology is at the lead optimization phase of its medicinal chemistry program. The Company anticipates that once results of the medicinal chemistry program being conducted by ChemDiv, Inc. are available, we should be in a position to form alliances with large companies interested in NR2F6 inhibition for cancer therapy or NR2F6 activation for treating autoimmune disorders.
https://finance.yahoo.com/news/regen-biopharm...00603.html
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!